Expanded Access Protocol for ANKTIVA in the Treatment of Lymphopenia: The company also announced it has submitted to the FDA an EAP to make available ANKTIVA for the treatment of lymphopenia.

Rates of neutropenia, lymphopenia, and infections were lower in the patients receiving avacopan than those who were not.

Expanded access protocol for Anktiva in the treatment of lymphopenia: The company also announced it has submitted to the US FDA an EAP to make available Anktiva for the treatment of lymphopenia.

In Q2, the company submitted to the U.S. Food and Drug Administration (FDA) an Expanded Access Protocol (EAP) for ANKTIVA for the treatment of lymphopenia as a BioShield against the adverse ...